May 3, 2017 7:36pm
… A lot of it noise and clamor with limited results
As the message continues to drown share pricing
… The message needs to be validated; it’s not the story but identifying value
Quantifying the message will rule share pricing by those who deliver it !
Pre-open indications: 6 hit and 1 miss – Organovo (ONVO) by pennies
Q1/17 financial results: Bluebird Bio (BLUE) reported a Q1 loss of $68.7 million or -$1.68 per share. The results surpassed “street” expectations. The average estimate was for a loss of $1.72 per share. BLUE posted revenue of $6.8 million, also surpassing “street” forecasts having an expectation of $1.5 million.
The truth is harsh, but reality is what it is!
I answer one question, in which company should investors commit and keep their money
RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.
Henry’omics:
From the pre-open’s investor’s newsletter “show me yours” and we will show you … What’s needed in the sector – not run of the mill, but significant holdings … … Of personal BUYING from board of directors, managements and employees.”
- Referencing this morning’s title, “Make a REAL statement of support by large investments in the current share pricing – its ownership NOT options!”
Looking forward, I believe investors will be focused on Q1/17 financial results – Aduro Biotech met some expectation and prospered in today’s session while bluebird bio (BLUE) surpassed “street” expectations.
- So far so good!
Athersys’ (ATHX) Q1 will hit the street on the 4th – wait and see – I am skeptical!
My TWO word for all – GUIDANCE and TRANSPARENCY …
The “stories” are drowning in the arrogance of some CEOs which will be their downfall with investors – I KNOW who they are … do you?
Q1/17 Financial results a.k.a. earnings:
Bluebird Bio Inc. (BLUE) reported a Q1 loss of $68.7 million in its first quarter off $1.68 per share. The results surpassed “street” expectations. The average estimate was for a loss of $1.72 per share. BLUE posted revenue of $6.8 million, also surpassing “street” forecasts. Analysts expected $1.5 million.
BLUE shares have risen 41% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $87.25, more than doubling in the last 12 months.
Daily analytics:
U.S. equities closed mostly flat on Tuesday … with the DOW closing up +0.04% as the NASDAQ closed down -0.37% …
… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 10.7 … which was up …
· Tuesday traded near 9.90 following Monday trading near 10.2,Friday traded near 10.9,Thursday’s near 10.77 and last Wednesday near 10.8;
Welcome to another day of the sector’s roller coaster …
… The iShares Russell 2000 (IWM) indicated a negative -0.29% at the pre-open was and closed DOWN -0.62%;
… The iShares NASDAQ Biotechnology (IBB) did NOT indicate at the pre-open and closed DOWN -0.65%
The advance/decline line scenario of 43 SCGT & RT covered companies:
· The open was negative with an A/DL of 16/23 and 4 flats;
· The mid-day stayed negative with an A/DL of 12/26 and 5 flats;
· The close was negative with an A/DL of 14/24 and 5 flats;
Wednesday’s count after Tuesday’s and Monday’s as compared to Friday’s range - decliners versus gainers:
Wednesday’s decliners ranged from -0.15% <BSTG> to -7.02% <RGNX> in 24 equities;
· Tuesday’s decliners ranged from -0.04% <CLLS> to -7.19% <RGNX> in 29 equities;
· Monday’s decliners ranged from -0.28% <NWBO> to -10.81% <AST> in 8 equities;
· Friday’s decliners ranged from -0.11% <BLUE> to -3.90% <AST> in 26 equities;
Wednesday’s gainers ranged from +0.20% <CLLS> to +4.95% <BLFS> in 14 equities;
· Tuesday’s gainers ranged from +0.28% <NWBO> to +5.11% <MDXG> in 13 equities;
· Monday’s gainers ranged from +0.02% <MESO> to +12.12% <VTGN> in 33 equities;
· Friday’s gainers ranged from +2.53% <BSTG> to +11.32% <MDXG> in 16 equities;
Pre-open indications: 6 hit and 1 miss
· Aduro Biotech (ADRO) closed up +$0.40 – hit;
· bluebird bio (BLUE) closed down -$0.90 – hit;
· Capricor (CAPR) closed flat at $3.29 – hit;
· Kite Pharma (KITE) closed down -$0.28 – hit;
· Organovo (ONVO) closed down -$0.04 – miss;
· Pluristem (PSTI) closed up +$0.01 – hit;
· Vericel (VCEL) closed up +$0.03 – hit;
Percentage gainers:
· BioLife Solutions (BLFS) +4.95%,
· MiMedx (MDXG) +4.78% after Tuesday’s +5.11%,
· Fibrocell (FCSC) +4.17% after Tuesday’s -4.95% after Monday’s -3.81% after Friday’s -3.23%,
· Aduro Biotech (ADRO) +4.15%,
· Osiris (OSIR) +2.24% after Tuesday’s +2.05%.
Percentage losers:
· Regenxbio (RGNX) -7.02% after Tuesday’s -7.19% after Monday’s +6.46%,
· Fate Therapeutics (FATE) -5.29% after Tuesday’s +1.94%
· Stemline (STML) -5.20%,
· Opexa (OPXA) -4.11%,
· Asterias Biotherapeutics (NYSEMKT: AST) -3.08%,
Dollar gainers:
· MiMedx (MDXG) +$0.62 after Tuesday’s +$0.63 after Monday’s -$0.36 after Friday’s+$1.29 after Thursday’s +$0.30,
· Aduro Biotech (ADRO) +$0.40,
· Mesoblast (MESO) +$0.21,
· Osiris (OSIR) +$0.11 after Tuesday’s +$0.10,
· Applied Genetic Technologies (AGTC) +$0.10,
Dollar losers:
· Regenxbio (RGNX) -$1.45 after Tuesday’s -$1.60 after Monday’s +$1.35,
· bluebird bio (BLUE) -$0.90 after Tuesday’s -$2.45 after Monday’s +$1.65,
· Stemline (STML) -$0.45 after Tuesday’s flat,
· Juno Therapeutics (JUNO) -$0.43 after Tuesday’s +0.21,
· Spark Therapeutics (ONCE) -$0.40 after Tuesday’s -$0.84 after Monday’s +$1.96 after Friday’s +$0.13 after Thursday’s +$0.60 after last Wednesday’s +$0.32,
Flats:
· ReNeuron (RENE.L),
· Cytori (CYTX),
· Adverum (ADVM),
· Cesca therapeutics (KOOL),
· Capricor (CAPR)
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
